At a glance
ClinicalIndex Comparison RecordN/ACompleted· 36 enrolled
Drug / intervention
Insulin Lispro +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Participant Adherence and Glucose Control While Using a Connected Insulin Management Platform
In Brief
A clinical study evaluating Insulin Lispro, Tempo Smart Button, and 2 other interventions for Type 1 Diabetes and 2 related conditions. Completed, enrolled 36 participants across 9 sites.
Detailed Summary
The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
202420252026
First PostedJun 2023
Enrollment StartOct 2023
Primary CompletionSep 2024
TodayJul 2026
First PostedJun 8, 2023
Enrollment StartOct 5, 2023
Primary CompletionSep 16, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.1 years ago
Interventions
Insulin Lisprodrug
As prescribed.
Tempo Smart Buttondevice
Attached to the Tempo Pen
Dexcom G6 CGMdevice
Continuous glucose monitor
Glooko Research Mobile App (RMA)device
Installed on a study provided android phone.